Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23636447 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL20305724 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL243267 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL23636486 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL5691531 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL50342 | 0.96 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1GAAMGAM | |
| Methyl Alcohol SCHEMBL28326399 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL28174051 | 0.93 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL28137354 | 0.93 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1GAAMGAM | |
| SCHEMBL21068431 | 0.92 | KMT2A (0.48) | ALDH1A1KMT2AMEN1GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629698-B2 | Frothers for minerals recovery and methods of making and using same | SYENSQO SA (BE) | 2026-05-19 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12533681-B2 | Frothers for minerals recovery | SYENSQO SA (BE) | 2026-01-27 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| EP-2292707-B1 | INK COMPOSITION FOR FORMING AN INSULATING FILM AND AN INSULATING FILM FORMED FROM SAID INK COMPOSITION | DAINIPPON INK & CHEMICALS (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-8791173-B2 | Ink composition for forming insulating film and insulating film formed from the ink composition | DIC CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110086946-A1 | INK COMPOSITION FOR FORMING INSULATING FILM AND INSULATING FILM FORMED FROM THE INK COMPOSITION | DIC CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2292707-A1 | INK COMPOSITION FOR FORMING AN INSULATING FILM AND AN INSULATING FILM FORMED FROM SAID INK COMPOSITION | DIC Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-4267260-A | Developer for lithographic printing plate | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885KMT2A 445/4885MEN1 4055/4885 |
| US-12533681-B2 | Frothers for minerals recovery | SF1, AFF1, AFF2 | ALDH1A1 2098/4885KMT2A 4604/4885MEN1 3504/4885 |
| US-12629698-B2 | Frothers for minerals recovery and methods of making and using same | CALCB, CA2, CALCR | ALDH1A1 3220/4885KMT2A 3890/4885MEN1 2906/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885KMT2A 445/4885MEN1 4055/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | ALDH1A1 3935/4885KMT2A 1067/4885MEN1 3886/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | ALDH1A1 3663/4885KMT2A 2161/4885MEN1 2198/4885 |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | ALDH1A1 3773/4885KMT2A 874/4885MEN1 2768/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | ALDH1A1 3742/4885KMT2A 928/4885MEN1 4186/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885KMT2A 445/4885MEN1 4055/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | ALDH1A1 333/4885KMT2A 2404/4885MEN1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.